"In our view, the ability to generate high quality wet-lab data is critical for advancement," analyst says in initiating ...

On Monday, Absci Corp (ABSI) stock saw a decline, ending the day at $3.81 which represents a decrease of $-0.19 or -4.75% from the prior close of $4. The stock opened at $3.88 and touched a low of ...

We recently compiled a list of the Top 10 Medical AI Stocks on Wall Street’s Radar. In this article, we are going to take a ...

Cathie Wood's ARK ETFs have made their daily trades public for Thursday, January 23rd, 2025, displaying a strategic shift in ...

Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Ballentine Partners LLC bought a new stake in Absci Co. (NASDAQ:ABSI – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 10,424 shares of the company’s stock, valued at ...

We recently published a list of Complete List of All AI Companies Under $2 Billion Market Cap. In this article, we are going ...

Needham analyst Gil Blum initiated coverage of Absci (ABSI) with a Buy rating and $9 price target Absci “stands out from the pack due to its ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.14, a high estimate of $10.00, and a low estimate of $5.00. This current average represents a 2.06% ...

Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...

Equities research analysts at Needham & Company LLC assumed coverage on shares of Absci (NASDAQ:ABSI – Get Free Report) in a ...

This approach allows Absci to quickly advance and monetize clinical-stage assets, aligning well with its AI/ML-driven platform. Price Action: ABSI stock is up 23% at $3.96 at the last check on ...